<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Emergent Biosolutions Inc — News on 6ix</title>
<link>https://6ix.com/company/emergent-biosolutions-inc</link>
<description>Latest news and press releases for Emergent Biosolutions Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 12:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/emergent-biosolutions-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683560ec78dffbe2df0ee361.webp</url>
<title>Emergent Biosolutions Inc</title>
<link>https://6ix.com/company/emergent-biosolutions-inc</link>
</image>
<item>
<title>Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-and-substipharm-biologics-announce-strategic-manufacturing-partnership-to-support-japanese-encephalitis-vaccine-in-the-united-states</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-and-substipharm-biologics-announce-strategic-manufacturing-partnership-to-support-japanese-encephalitis-vaccine-in-the-united-states</guid>
<pubDate>Tue, 28 Apr 2026 12:01:00 GMT</pubDate>
<description>Emergent’s Canton facility will manufacture drug substance and obtains exclusive distribution rights GAITHERSBURG, Md. and GENEVA, April 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has entered into an agreement with Substipharm Biologics valued at approximately $34.5 million to support drug substance manufacturing for its Japanese Encephalitis (JE) vaccine, licensed internationally under the brand name IMOJEV® at Emergent’s Canton, Massachusetts facilit</description>
</item>
<item>
<title>Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-to-report-first-quarter-2026-financial-results-on-april-30-2026</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-to-report-first-quarter-2026-financial-results-on-april-30-2026</guid>
<pubDate>Thu, 16 Apr 2026 20:05:00 GMT</pubDate>
<description>GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 30, 2026, at 5:00 p.m. eastern time to discuss the financial results for the first quarter of 2026. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a conf</description>
</item>
<item>
<title>Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-partners-with-british-columbia-to-supply-narcanr-nasal-spray-for-the-launch-of-the-expanded-bc-take-home-naloxone-program</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-partners-with-british-columbia-to-supply-narcanr-nasal-spray-for-the-launch-of-the-expanded-bc-take-home-naloxone-program</guid>
<pubDate>Thu, 09 Apr 2026 20:25:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, April 09, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply NARCAN® Nasal Spray for the province’s Take-Home Naloxone Program (BC THN Program). This order follows an additional investment of $18 million CAD by the B.C. government to expand the BC THN Program to include nasal naloxone. This is an expansion of B.C.’s nasal naloxone pilot program, which launched in</description>
</item>
<item>
<title>Emergent BioSolutions Launches New NARCAN® Nasal Spray Carrying Case and Multipacks Alongside College Campus Outreach to Expand Opioid Overdose Preparedness</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-launches-new-narcanr-nasal-spray-carrying-case-and-multipacks-alongside-college-campus-outreach-to-expand-opioid-overdose-preparedness</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-launches-new-narcanr-nasal-spray-carrying-case-and-multipacks-alongside-college-campus-outreach-to-expand-opioid-overdose-preparedness</guid>
<pubDate>Tue, 07 Apr 2026 12:05:00 GMT</pubDate>
<description>New product offerings and educational initiative, Ready to Rescue, aim to increase access and adoption of NARCAN® Nasal Spray to empower communities to save a life in an opioid overdose emergency NARCAN® Nasal Spray Multipacks Now Available: NARCAN® Nasal Spray Multipacks NARCAN® Nasal Spray Carrying Case Now Available: NARCAN® Nasal Spray Carrying Case NARCAN® Nasal Spray Carrying Case Now Available: NARCAN® Nasal Spray Carrying Case GAITHERSBURG, Md., April 07, 2026 (GLOBE NEWSWIRE) -- Emergen</description>
</item>
<item>
<title>Emergent BioSolutions Participates in Upcoming International Preparedness Conferences</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-participates-in-upcoming-international-preparedness-conferences-50</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-participates-in-upcoming-international-preparedness-conferences-50</guid>
<pubDate>Thu, 02 Apr 2026 12:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global life sciences leader with biodefense and medical countermeasures products, announced today that members of its products business, medical affairs, government and public affairs teams will participate in the following international preparedness conferences: London Defence Conference, April 10-11, London, United KingdomCBRN Research & Innovation Conference, May 19-21, Arcachon, FranceGlobal Healt</description>
</item>
<item>
<title>Emergent BioSolutions Secures over $60 Million in New Contract Award with the U.S. Government and New Orders with an International Government Partner for Smallpox Medical Countermeasures</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-secures-over-dollar60-million-in-new-contract-award-with-the-us-government-and-new-orders-with-an-international-government-partner-for-smallpox-medical-countermeasures</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-secures-over-dollar60-million-in-new-contract-award-with-the-us-government-and-new-orders-with-an-international-government-partner-for-smallpox-medical-countermeasures</guid>
<pubDate>Wed, 25 Mar 2026 20:15:00 GMT</pubDate>
<description>GAITHERSBURG, Md., March 25, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at approximately $54 million USD to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), part of the U. S. Department of Health and Human Services (HHS), for smallpox preparedness. ASPR exercised an option from its existing 10-year contract (75A50119C00037) for a</description>
</item>
<item>
<title>Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-announces-appointment-of-john-d-fowler-jr-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-announces-appointment-of-john-d-fowler-jr-to-board-of-directors</guid>
<pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings more than three decades of leadership experience across the healthcare and financial services sectors. He will serve on the Audit and Finance Committee. “We’re pleased to welcome John to the board of directors at this important point in the company’s ongoing turnaround and transform</description>
</item>
<item>
<title>Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 21:05:00 GMT</pubDate>
<description>Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFu</description>
</item>
<item>
<title>Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-announces-approximately-dollar140-million-in-contract-awards-with-the-government-of-canada-strengthening-canadas-leadership-in-health-preparedness</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-announces-approximately-dollar140-million-in-contract-awards-with-the-government-of-canada-strengthening-canadas-leadership-in-health-preparedness</guid>
<pubDate>Thu, 26 Feb 2026 21:01:00 GMT</pubDate>
<description>WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada’s biological threat preparedness and response infrastructure. The multiyear agreements, valued at up to approximately $140 million CAD, build upon over a decade of collaboration between Em</description>
</item>
<item>
<title>Emergent BioSolutions Announces New $50 Million Stock Repurchase Program</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-announces-new-dollar50-million-stock-repurchase-program</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-announces-new-dollar50-million-stock-repurchase-program</guid>
<pubDate>Thu, 26 Feb 2026 21:01:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company’s common stock on or before March 31, 2027. This authorization replaces the prior repurchase authorization which permitted Emergent to repurchase up to $50 million of company’s common stock by March 27, 2026. Under the prior authorization, Emergent repurchased $24.8 million shares. “In 2025, we were a</description>
</item>
<item>
<title>Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-receives-u-fda-230000656</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-receives-u-fda-230000656</guid>
<pubDate>Thu, 12 Feb 2026 23:00:00 GMT</pubDate>
<description>Approval will broaden the NARCAN® Nasal Spray portfolio, and improve cost-effectiveness by increasing flexibility and distribution efficiency of this life-saving medication GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for new multipack configurations of over-the-counter (OTC) NARCAN® Nasal Spray. This approval expands the NARCAN® Na</description>
</item>
<item>
<title>Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-report-fourth-quarter-140200738</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-report-fourth-quarter-140200738</guid>
<pubDate>Thu, 12 Feb 2026 14:02:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent’s website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will</description>
</item>
<item>
<title>Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-receives-u-fda-130000019</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-receives-u-fda-130000019</guid>
<pubDate>Wed, 14 Jan 2026 13:00:00 GMT</pubDate>
<description>Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective way to reverse opioid overdoses, and today, new solutions like the NARCAN® carrying case aims to make accessibility paramount - ‘Trusted Then. Trusted Now’ GAITHERSBURG, Md., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for over-the-counter (OTC)</description>
</item>
<item>
<title>Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-announces-100-million-123000190</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-announces-100-million-123000190</guid>
<pubDate>Mon, 12 Jan 2026 12:30:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions, Inc. (NYSE: EBS) announced it made a voluntary prepayment of $100 million under its outstanding term loan facility in late December 2025 using cash on hand. “This significant milestone reflects strong progress in improving our overall financial/cash position, enhancing our financial flexibility and positioning Emergent for long-term stability and growth,” stated Joe Papa, president and CEO of Emergent. “We continue</description>
</item>
<item>
<title>Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-receives-delivery-order-213000210</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-receives-delivery-order-213000210</guid>
<pubDate>Thu, 08 Jan 2026 21:30:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced it has received a delivery order valued at up to $21.5 million from the U.S. Department of War to supply BioThrax® (Anthrax Vaccine Adsorbed) in 2026. This order is under Emergent’s existing indefinite-delivery/indefinite-quantity (IDIQ) contract (W911SR24D0001), led by the Capability Program Executive Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), previously the Joint Prog</description>
</item>
<item>
<title>Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-panther-announce-agreement-130000819</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-panther-announce-agreement-130000819</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md. and PARIS and ADDIS ABABA, Ethiopia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced a collaboration agreement with PANTHER to provide additional financial support to continue progressing the Africa CDC-led ‘MpOx Study in Africa’ (MOSA). This initiative aims to advance research into effective treatments for patients diagnosed with mpox, a virus for which there is currently no dedicated antiviral therapy. Launched in 2024, MOSA is a double-bli</description>
</item>
<item>
<title>Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-present-44th-annual-125900423</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-present-44th-annual-125900423</guid>
<pubDate>Wed, 07 Jan 2026 12:59:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that Joe Papa, president and chief executive officer, will provide a company presentation during the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 5:15 PM PST. The audio link for Emergent’s session may be accessed here and will be live for up to 30 days. The Company’s slides will be made available at the time of the presentation on the Investors section of</description>
</item>
<item>
<title>Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-receives-u-fda-133000086</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-receives-u-fda-133000086</guid>
<pubDate>Fri, 12 Dec 2025 13:30:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for its Winnipeg, Canada facility to be added as the drug product manufacturing and testing site for raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax. “We are pleased with the U.S. FDA approval of our sBLA for raxibacumab manufacturing a</description>
</item>
<item>
<title>Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-marks-10-anniversary-130000732</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-marks-10-anniversary-130000732</guid>
<pubDate>Tue, 18 Nov 2025 13:00:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN® (naloxone HCl) Nasal Spray as the first FDA-approved nasal naloxone spray for emergency treatment of opioid overdose. This historic approval made the life-saving medication easy to administer in both medical and community settings, ultimately leading to NARCAN® Nasal Spray becoming the first FDA-approved</description>
</item>
<item>
<title>Emergent BioSolutions Announces Retirement of Dr. Louis W. Sullivan from Board of Directors</title>
<link>https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-announces-retirement-dr-210100100</link>
<guid isPermaLink="true">https://6ix.com/company/emergent-biosolutions-inc/news/emergent-biosolutions-announces-retirement-dr-210100100</guid>
<pubDate>Wed, 12 Nov 2025 21:01:00 GMT</pubDate>
<description>GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W. Sullivan will retire from the company’s Board of Directors effective November 14 after 19 years of service to the company and its shareholders. “For nearly two decades, Dr. Sullivan has been a trusted advisor and champion of Emergent’s mission to protect and save lives,” said Joe Papa, president and CEO of Emergent. “On behalf of the Board and the entire Emergent team, I want</description>
</item>
</channel>
</rss>